Eli Lilly

There’s no denying modern-day artificial intelligence (AI) is doing some pretty cool stuff. But, to say it’s been…

Wight loss drug company Novo Nordisk will expand its facility in Athlone, chief executive Mike Doustdar says. The…

New global partnership aims to turn PepLib’s peptide tech into therapies that could reshape treatment and longevity. Think…

Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are rivals in the GLP-1 drug market and are…

Super Bowl Sunday is the holy grail of advertising thanks to its massive viewership, with an average of…

Feb 5 (Reuters) – Hims & Hers said it would begin offering compounded versions of Novo Nordisk’s Wegovy…

Eli Lilly’s (NYSE: LLY) share price jumped 39% in 2025, driven by investors eager to benefit from the…

Eli Lilly has made several moves to boost its artificial intelligence (AI) capacity. It could help complement its…

Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its…

Eli Lilly (NYSE: LLY) delivered a gain worthy of a technology growth stock last year. The pharma giant’s…

WASHINGTON (AP) — The Food and Drug Administration commissioner’s effort to drastically shorten the review of drugs favored…

Retatrutide’s recent trial results suggest it may be even better than Eli Lilly’s already approved GLP-1 medication, tirzepatide.…

This Pharma Giant Is Using AI to Dominate Drug Discovery